Search

Search Constraints

You searched for: Author/Creator de Schaetzen, Gaetan

Search Results

1. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Issue 5 (May 2015)

2. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. (September 2020)

3. Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58 Late Adverse Effects study. Issue 1 (11th November 2021)

4. Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukaemia Survivors Enrolled Between 1971 and 1998 in EORTC CLG Studies: Results of the 58 Late Adverse Effects Study. Issue 4 (April 2022)

5. Lessons learnt from the medical and psychosocial evaluation of childhood acute lymphoblastic leukemia (ALL) survivors enrolled in EORTC Children Leukemia Group Trials between 1971 and 1998 and future perspectives for long-term outcome research. (May 2018)

6. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. (March 2016)

7. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy. (22nd August 2017)

8. Socio‐economic outcomes among long‐term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: Results of the 58LAE study. (25th October 2022)